Name: 글로벌 시장 동향
SKU: PH4035
Availability: InStock

보고서 요약(국문)

시장 개요
세계 항트롬빈 시장은 2022년 5억 4,500만 달러에 달했으며, 2030년까지 7억 7,570만 달러에 이르러 높은 성장세를 보일 것으로 예상됩니다. 세계 항트롬빈 시장은 2023년부터 2030년까지 연평균 4.6%의 성장률을 기록할 것으로 전망됩니다.
심혈관 질환의 유병률 증가, 유전성 항트롬빈 결핍증 치료를 위한 항트롬빈 요법 수요 증가, 항트롬빈 분야의 연구 개발 활동 증가, 그리고 수술 절차에서의 항트롬빈 사용 증가 등이 세계 항트롬빈 시장 성장에 영향을 미칠 주요 시장 동향입니다.
예를 들어, 샌프란시스코 캘리포니아 대학교 연구진이 Science Translational Medicine 저널에 발표한 연구에 따르면, 항트롬빈 결핍증은 혈전증을 유발할 수 있는 유전 질환입니다. 과학자들은 CRISPR-Cas9 유전자 편집 기술을 이용하여 질병에 걸린 환자의 혈액 세포를 유도만능줄기세포(iPSC)로 변형시키는 유전자 편집 치료법을 개발했습니다.
이렇게 변형된 iPSC는 항트롬빈을 생성하는 간세포인 간세포로 분화됩니다. 그런 다음 이 간세포를 항트롬빈 결핍증이 있는 쥐에 이식하면 혈전 형성이 감소합니다. 이 연구는 CRISPR-Cas9 기술이 유전적 이상을 복구할 수 있는 잠재력을 보여주며, 유전성 항트롬빈 결핍증에 대한 혁신적인 치료법 개발에 대한 희망을 제시합니다.
항트롬빈(AT)은 간에서 합성되는 464개의 아미노산으로 구성된 당단백질입니다. 세 개의 이황화 결합과 네 개의 당화 부위를 가지고 있습니다. AT는 세린 프로테아제 억제제로 작용하는 세르핀 계열 단백질입니다. AT는 응고 과정에 관여하는 여러 프로테아제에 결합하여 비활성화시킬 수 있습니다. 프로테아제에는 트롬빈, 인자 Xa, 인자 IXa, 인자 XIa, 인자 XIIa 등이 있습니다. 항트롬빈(AT)의 억제 활성은 필수 항응고 단백질인 단백질 C와 S에도 미칩니다.
정맥혈전색전증(VTE) 발생률 증가, 다양한 임상 환경에서 치료제로 사용되는 항트롬빈에 대한 수요 증가, 그리고 새로운 항트롬빈 제품 및 치료법 개발은 예측 기간 동안 세계 항트롬빈 시장 성장을 견인할 것으로 예상되는 요인입니다.
예를 들어, 옥타파마(Octapharma)는 선천성 항트롬빈 결핍증이 있는 수술 또는 출산 환자를 대상으로 아테나티브(Atenativ)의 효능을 평가하기 위한 임상 시험을 진행하고 있습니다. 이러한 요인들이 세계 항트롬빈 시장에 영향을 미치고 있습니다.
시장 동향
심혈관 질환 유병률 증가가 세계 항트롬빈 시장 성장을 주도하고 있습니다.
전 세계적으로 심혈관 질환은 사망 및 장애의 주요 원인입니다. 심혈관 질환의 발병은 고혈압, 고콜레스테롤, 흡연, 비만 등 여러 변수의 영향을 받습니다.
예를 들어, 미국 심장 협회의 2023년 심장 질환 및 뇌졸중 통계 보고서에 따르면, 2020년 미국에서 심혈관 질환으로 사망한 사람은 928,741명이었으며, 이 중 관상동맥 질환(CHD)이 41.2%를 차지했고, 그 다음으로 뇌졸중이 많았습니다. 따라서 이러한 이유로 심혈관 질환의 유병률 증가는 예측 기간 동안 전 세계 항트롬빈 시장 성장을 견인할 것입니다.
항트롬빈 제품의 높은 가격은 전 세계 항트롬빈 시장 성장을 저해하는 요인입니다.
항트롬빈 약물의 높은 가격에는 여러 요인이 작용합니다. 합성 의약품과 달리 항트롬빈은 여러 사람의 혈장을 모아서 만들기 때문에 원료 자체가 고가입니다. 또한, 항트롬빈 제품 생산은 고도의 정제 및 농축이 필요하기 때문에 전반적으로 더 복잡하고 비용이 많이 듭니다.

또한, 다른 치료법과 비교했을 때 항트롬빈 제제는 시장 규모가 작고 경쟁이 적어 가격 경쟁이 덜 치열합니다. 마지막으로, 항트롬빈 제품은 주로 중증 항트롬빈 결핍증이라는 희귀 질환을 치료하는 데 사용되므로 전 세계 항트롬빈 시장 규모를 제한하고 가격 상승에 기여합니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 항트롬빈 시장에 상당한 영향을 미쳤습니다. 수술 건수 감소와 정맥혈전색전증(VTE)과 같은 질환 진단 감소로 인해 항트롬빈 수요가 감소했습니다. 이러한 어려움에도 불구하고 시장은 향후 성장할 것으로 예상됩니다. 심혈관 질환 발병률 증가, 항트롬빈 치료의 이점에 대한 인식 제고, 새로운 항트롬빈 제제 개발의 발전 등 여러 요인이 이러한 성장을 촉진할 것입니다.
러시아-우크라이나 분쟁 분석
러시아와 우크라이나 간의 지속적인 분쟁은 전 세계 항트롬빈 시장에 악영향을 미쳐 공급량을 감소시켰습니다. 러시아에 대한 제재, 공급망 차질, 생산량 감소는 이러한 하락세에 기여한 여러 원인 중 일부에 불과합니다. 항트롬빈 공급량 감소로 인해 가격이 상승하여 환자들이 약을 구매하기가 더욱 어려워졌습니다.
여러 가지 상황으로 인해 분쟁 또한 항트롬빈 수요 감소로 이어졌습니다. 의료 서비스 접근성 저하, 경제적 부담 증가, 그리고 폭력 사태로 피해를 입은 사람들의 불안감 증가 등이 그 원인입니다. 러시아-우크라이나 분쟁은 세계 항트롬빈 시장에 단기적으로 부정적인 영향을 미칠 것으로 예상됩니다.
세분화 분석
세계 항트롬빈 시장은 용도, 원산지, 투여 경로, 유형 및 지역별로 세분화됩니다.
주사제 형태의 항트롬빈은 예측 기간 동안 세계 항트롬빈 시장에서 지배적인 위치를 차지할 것으로 예상됩니다.

주사 투여 방식은 2022년 항트롬빈 시장에서 약 64.4%의 점유율을 차지하며 가장 높은 시장 점유율을 기록했습니다. 주사 투여 방식의 항트롬빈 약물은 주로 정맥 주사로 투여됩니다. 정맥 주사는 항트롬빈을 혈액 순환계로 신속하게 전달하여 빠르고 효과적인 치료를 제공하기 때문에 중증 항트롬빈 결핍증 환자에게 흔히 사용됩니다.
트롬베이트 III는 순수 인간 항트롬빈 III 제품으로, 무균 상태의 안정적인 동결건조 제제입니다. 이는 원발성 및 후천성 항트롬빈 결핍증 치료에 모두 사용됩니다. 건강한 기증자로부터 채취한 인간 혈장 풀을 사용하여 제조됩니다. 트롬베이트 III는 방부제를 함유하지 않으며 정맥 주사로만 투여해야 합니다. 따라서 이러한 요인들로 인해 주사 투여 방식은 예측 기간 동안 전 세계 항트롬빈 시장에서 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.

지리적 분석
북미는 세계 항트롬빈 시장에서 지배적인 위치를 차지하고 있습니다.
심부정맥혈전증(DVT), 폐색전증, 뇌졸중과 같은 혈전성 질환의 발병 위험이 고령화에 따라 증가함에 따라 북미는 예측 기간 동안 전체 시장 점유율의 약 38.8%를 차지할 것으로 예상됩니다. 노인 환자는 여러 동반 질환, 수술 이력, 운동 능력 저하 등 혈전 발생 위험을 높이는 요인들을 가지고 있습니다. 베이비붐 세대가 은퇴 연령에 접어들면서 미국은 고령 인구가 상당히 증가하고 있습니다.
예를 들어, 미국 인구조사국의 2023년 보고서에 따르면, 2021년 미국 지역사회 조사(American Community Survey)에서 미국 내 65세 이상 인구는 5,589만 2,014명으로 전체 인구 3억 3,189만 3,745명의 16.8%를 차지했습니다.

또한, 항트롬빈 치료의 이점에 대한 인식이 높아지고 수술을 받는 환자 수가 증가하며, 주요 시장 참여 기업이 해당 지역에 존재하기 때문에 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
경쟁 환경
시장의 주요 글로벌 기업으로는 CSL Limited, Grifols SA, Takeda Pharmaceuticals, Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, Lee Biosolutions Inc., BDI Pharma 등이 있습니다.
보고서 구매 이유

• 사용 용도, 유형, 투여 경로, 공급원 및 지역별 글로벌 항트롬빈 시장 세분화를 시각화하고 주요 상업적 자산과 기업을 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 항트롬빈 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.
글로벌 항트롬빈 시장 보고서는 약 49개의 표, 53개의 그림, 그리고 195페이지 분량입니다.
2023년 주요 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Antithrombin Market reached US$ 545 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 775.7 million by 2030. The global antithrombin market is expected to exhibit a CAGR of 4.6% during the forecast period 2023-2030.
The increasing prevalence of cardiovascular diseases, rising demand for antithrombin therapy in the treatment of hereditary antithrombin deficiency, growing research and development activities in the field of antithrombin, and growing adoption of antithrombin in surgical procedures are some of the antithrombin market trends that will influence the Global Antithrombin Market.
For instance, a study conducted by researchers at the University of California, San Francisco, published in the journal Science Translational Medicine, Antithrombin deficiency is a hereditary disease that can lead to blood clotting. Scientists have created a gene-editing therapy that transforms blood cells from afflicted patients into pluripotent stem cells (iPSCs) using the CRISPR-Cas9 gene-editing technology to treat this disease.
Then altered iPSCs are transformed into hepatocytes, liver cells that make antithrombin. These hepatocytes are subsequently implanted into mice with antithrombin deficiencies, reducing blood clot formation. This work demonstrates CRISPR-Cas9's potential for repairing genetic abnormalities and holds hope for developing innovative therapeutics for hereditary antithrombin deficiency.
Antithrombin (AT) is a 464 amino acid glycoprotein synthesized in the liver. It has three disulfide bonds and four glycosylation sites. AT is a serpin family member that functions as a serine protease inhibitor. It can bind to and deactivate numerous proteases involved in the coagulation process. Among the proteases are thrombin, factor Xa, factor IXa, factor XIa, and factor XIIa. AT's inhibitory activity extends to proteins C and S, both of which are essential anticoagulant proteins.
The rising incidence of venous thromboembolism (vte), growing demand for antithrombin as a therapeutic agent in various clinical settings, and development of new antithrombin products and therapies are the factors expected to drive the global antithrombin market over the forecast period.
Development of new antithrombin product, for instance, Octapharma, is conducting a clinical trial to evaluate the efficacy of Atenativ in individuals having surgery or delivery who have congenital antithrombin deficiency. These are the factors influencing the global antithrombin market.
Market Dynamics
Increased Prevalence of Cardiovascular Disease is Driving the Global Antithrombin Market Growth.
On a global level, cardiovascular disease is a major cause of mortality and disability. Its development is influenced by several variables, including as high blood pressure, high cholesterol, smoking, and obesity.
For instance, according to the American Heart Association’s Heart Disease and Stroke Statistics report of 2023, 928,741 deaths were seen in the U.S. in 2020 for cardiovascular disease, in which coronary heart disease (CHD) held 41.2% of deaths, followed by strokes. Therefore owing to these reasons, the growing prevalence of cardiovascular disease will drive the global antithrombin market over the forecast period.
The High Cost of Antithrombin Products is Hampering the Growth of the Global Antithrombin Market.
Various factors contribute to the higher cost of antithrombin drugs. In contrast to synthetic medications, they start off as expensive source materials since they are made from pooled human plasma. Second, the production of antithrombin products is more complicated and expensive overall due to the high degrees of purification and concentration required.
Moreover, compared to other therapies, antithrombin medicines have a smaller market and less competition, which results in less price competition. Last but not least, antithrombin products mainly treat a rare disease termed severe antithrombin deficiency, further limiting the global antithrombin market size and contributing to higher prices.
COVID-19 Impact Analysis
The COVID-19 pandemic has had significant effects on the Global Antithrombin Market. Antithrombin demand has decreased due to a decline in surgical operations and diagnosis of illnesses such as venous thromboembolism (VTE). The market is expected to grow in the future despite these obstacles. Several reasons, such as the rising incidence of cardiovascular disorders, more knowledge of the benefits of antithrombin therapy, and improvements in the creation of novel antithrombin medicines, will influence this expansion.
Russia-Ukraine Conflict Analysis
The ongoing conflict between Russia and Ukraine has hurt the global antithrombin market, which has reduced its supply. Sanctions on Russia, supply chain hiccups, and decreased output are just a few of the causes that contributed to this fall. Antithrombin costs have increased due to the reduced availability, making it more difficult for patients to purchase the medication.
Due to several circumstances, the conflict has also led to a decline in the demand for antithrombin. There is less access to healthcare services, less money to spend, and more fear and worry among those impacted by the violence. The Russia-Ukraine conflict is anticipated to have a short-term detrimental effect on the world antithrombin market.
Segment Analysis
The Global Antithrombin Market is segmented based on usage, source, route of administration, type, and region.
The Parenteral segment is expected to hold a dominant position for the global antithrombin market over the forecast period.
The Parenteral route accounted for the highest market share, accounting for approximately 64.4% of the antithrombin market in 2022. The preferred route of administration for antithrombin drugs in the Parenteral route is intravenous. Because the intravenous injection is frequently utilized to deliver antithrombin into the blood circulation swiftly, it provides prompt and effective therapy, it is commonly preferred for individuals with severe antithrombin insufficiency.
Thrombate III, a pure human antithrombin III product, is a sterile and stable lyophilized preparation. It is used to treat both primary and acquired antithrombin insufficiency. It is made from pooled units of human plasma collected from healthy donors. Thrombate III contains no preservatives and should only be taken intravenously. Thus, owing to the above factors, the market segment is expected to hold the largest market share for global antithrombin market over the forecast period.
Geographical Analysis
North America Holds a Dominant Position in the Global Antithrombin Market.
North America is expected to hold around 38.8% of the total market share throughout the forecast period, as the chance of having thrombotic illnesses such as deep vein thrombosis (DVT), pulmonary embolism, and stroke rises as people age. Geriatric patients may have several comorbidities, surgeries, and limited mobility, all of which increase their risk of blood clot development. With the baby boomer generation approaching retirement age and beyond, the United States has a considerable aging population.
For instance, according to the United States Census Bureau's 2023 report, the 2021 American Community Survey indicated 55,892,014 persons aged 65 and older in the U.S., or 16.8% of the total population of 331,893,745.
Moreover, the increasing awareness about the benefits of antithrombin therapy and the rising number of patients undergoing surgery, also the presence of a major market player in the region, is expected to hold the largest market share over the forecast period.
Competitive Landscape
The major global players in the market include CSL Limited, Grifols SA, Takeda Pharmaceuticals, Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, Lee Biosolutions Inc., BDI Pharma, among others.
Why Purchase the Report?
• To visualize the Global Antithrombin Market segmentation based on the usage, type, route of administration, source, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of antithrombin market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Antithrombin Market Report would Provide Approximately 49 Tables, 53 Figures, And 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Usage
3.2. Snippet by Type
3.3. Snippet by Route of Administration
3.4. Snippet by Source
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increased Prevalence of Cardiovascular Disease is Driving the Global Antithrombin Market Growth.
4.1.2. Restraints
4.1.2.1. The High Cost of Antithrombin Products is Hampering the Growth of the Global Antithrombin Market.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Post COVID-19 & Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. By Usage
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
8.1.2. Market Attractiveness Index, By Usage
8.2. Therapeutics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostics
8.4. Research
8.5. Other
9. By Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.1.2. Market Attractiveness Index, By Type
9.2. Anticoagulant*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Antiplatelet
9.4. Thrombolytic Drug
10. By Route of Administration
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.1.2. Market Attractiveness Index, By Route of Administration
10.2. Oral*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Parenteral
11. By Source
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
11.1.2. Market Attractiveness Index, By Source
11.2. Human*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Recombinant Goat Milk
11.4. Others
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.7.1. The U.S.
12.2.7.2. Canada
12.2.7.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.7.1. Germany
12.3.7.2. The U.K.
12.3.7.3. France
12.3.7.4. Italy
12.3.7.5. Spain
12.3.7.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.7.1. Brazil
12.4.7.2. Argentina
12.4.7.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.6.1. China
12.5.6.2. India
12.5.6.3. Japan
12.5.6.4. Australia
12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies
14. Company Profiles
14.1. CSL Limited*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Grifols SA
14.3. Takeda Pharmaceuticals
14.4. Octapharma AG
14.5. LFB USA
14.6. Axis-Shield Plc
14.7. Siemens AG
14.8. Thermo Fisher Scientific
14.9. Lee Biosolutions Inc.
14.10. BDI Pharma
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

CSL Limited, 4.	Key Developments, Grifols SA, Takeda Pharmaceuticals, Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, Lee Biosolutions Inc., BDI Pharma

표 목록 (Tables)

List of Tables

Table 1 Global Antithrombin Market Value, By Usage, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Antithrombin Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Antithrombin Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Antithrombin Market Value, By Source, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Antithrombin Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Antithrombin Market Value, By Usage, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Antithrombin Market Value, By Usage, 2021-2030 (US$ Million)

Table 8 Global Antithrombin Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Antithrombin Market Value, By Type, 2021-2030 (US$ Million)

Table 10 Global Antithrombin Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Antithrombin Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 12 Global Antithrombin Market Value, By Source, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Antithrombin Market Value, By Source, 2021-2030 (US$ Million)

Table 14 Global Antithrombin Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Antithrombin Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Antithrombin Market Value, By Usage, 2021-2030 (US$ Million)

Table 17 North America Antithrombin Market Value, By Type, 2021-2030 (US$ Million)

Table 18 North America Antithrombin Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 North America Antithrombin Market Value, By Source, 2021-2030 (US$ Million)

Table 20 North America Antithrombin Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Antithrombin Market Value, By Usage, 2021-2030 (US$ Million)

Table 22 South America Antithrombin Market Value, By Type, 2021-2030 (US$ Million)

Table 23 South America Antithrombin Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 24 South America Antithrombin Market Value, By Source, 2021-2030 (US$ Million)

Table 25 South America Antithrombin Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Antithrombin Market Value, By Usage, 2021-2030 (US$ Million)

Table 27 Europe Antithrombin Market Value, By Type, 2021-2030 (US$ Million)

Table 28 Europe Antithrombin Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 29 Europe Antithrombin Market Value, By Source, 2021-2030 (US$ Million)

Table 30 Europe Antithrombin Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Antithrombin Market Value, By Usage, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Antithrombin Market Value, By Type, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Antithrombin Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Antithrombin Market Value, By Source, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Antithrombin Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Antithrombin Market Value, By Usage, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Antithrombin Market Value, By Type, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Antithrombin Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Antithrombin Market Value, By Source, 2021-2030 (US$ Million)

Table 40 CSL Limited: Overview

Table 41 CSL Limited: Product Portfolio

Table 42 CSL Limited: Key Developments

Table 43 Grifols SA: Overview

Table 44 Grifols SA: Product Portfolio

Table 45 Grifols SA: Key Developments

Table 46 Takeda Pharmaceuticals: Overview

Table 47 Takeda Pharmaceuticals: Product Portfolio

Table 48 Takeda Pharmaceuticals: Key Developments

Table 49 Octapharma AG: Overview

Table 50 Octapharma AG: Product Portfolio

Table 51 Octapharma AG: Key Developments

Table 52 LFB USA: Overview

Table 53 LFB USA: Product Portfolio

Table 54 LFB USA: Key Developments

Table 55 Axis-Shield Plc: Overview

Table 56 Axis-Shield Plc: Product Portfolio

Table 57 Axis-Shield Plc: Key Developments

Table 58 Siemens AG: Overview

Table 59 Siemens AG: Product Portfolio

Table 60 Siemens AG: Key Developments

Table 61 Thermo Fisher Scientific: Overview

Table 62 Thermo Fisher Scientific: Product Portfolio

Table 63 Thermo Fisher Scientific: Key Developments

Table 64 Lee Biosolutions Inc.: Overview

Table 65 Lee Biosolutions Inc.: Product Portfolio

Table 66 Lee Biosolutions Inc.: Key Developments

Table 67 BDI Pharma: Overview

Table 68 BDI Pharma: Product Portfolio

Table 69 BDI Pharma: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 2 Global Antithrombin Market Share, By Usage, 2022 & 2030 (%)

Figure 3 Global Antithrombin Market Share, By Type, 2022 & 2030 (%)

Figure 4 Global Antithrombin Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Antithrombin Market Share, By Source, 2022 & 2030 (%)

Figure 6 Global Antithrombin Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Antithrombin Market Y-o-Y Growth, By Usage, 2022-2030 (%)

Figure 8 Therapeutics Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 9 Diagnostics Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 10 Research Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 11 Others Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 12 Global Antithrombin Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 13 Anticoagulant Type in Global Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 14 Antiplatelet Type in Global Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 15 Thrombolytic Drug Type in Global Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 16 Global Antithrombin Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 17 Oral Route of Administration in Global Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 18 Parenteral Route of Administration in Global Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 19 Global Antithrombin Market Y-o-Y Growth, By Source, 2022-2030 (%)

Figure 20 Human Source in Global Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 21 Recombinant Goat Milk Source in Global Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 22 Others Source in Global Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 23 Global Antithrombin Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 24 North America Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 25 Asia-Pacific Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 26 Europe Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 27 South America Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 28 Middle East and Africa Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 29 North America Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 30 North America Antithrombin Market Share, By Usage, 2022 & 2030 (%)

Figure 31 North America Antithrombin Market Share, By Type, 2022 & 2030 (%)

Figure 32 North America Antithrombin Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 33 North America Antithrombin Market Share, By Source, 2022 & 2030 (%)

Figure 34 North America Antithrombin Market Share, By Country, 2022 & 2030 (%)

Figure 35 South America Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 36 South America Antithrombin Market Share, By Usage, 2022 & 2030 (%)

Figure 37 South America Antithrombin Market Share, By Type, 2022 & 2030 (%)

Figure 38 South America Antithrombin Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 39 South America Antithrombin Market Share, By Source, 2022 & 2030 (%)

Figure 40 South America Antithrombin Market Share, By Country, 2022 & 2030 (%)

Figure 41 Europe Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 42 Europe Antithrombin Market Share, By Usage, 2022 & 2030 (%)

Figure 43 Europe Antithrombin Market Share, By Type, 2022 & 2030 (%)

Figure 44 Europe Antithrombin Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 45 Europe Antithrombin Market Share, By Source, 2022 & 2030 (%)

Figure 46 Europe Antithrombin Market Share, By Country, 2022 & 2030 (%)

Figure 47 Asia-Pacific Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 48 Asia-Pacific Antithrombin Market Share, By Usage, 2022 & 2030 (%)

Figure 49 Asia-Pacific Antithrombin Market Share, By Type, 2022 & 2030 (%)

Figure 50 Asia-Pacific Antithrombin Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 51 Asia-Pacific Antithrombin Market Share, By Source, 2022 & 2030 (%)

Figure 52 Asia-Pacific Antithrombin Market Share, By Country, 2022 & 2030 (%)

Figure 53 Middle East & Africa Antithrombin Market Value, 2021-2030 (US$ Million)

Figure 54 Middle East & Africa Antithrombin Market Share, By Usage, 2022 & 2030 (%)

Figure 55 Middle East & Africa Antithrombin Market Share, By Type, 2022 & 2030 (%)

Figure 56 Middle East & Africa Antithrombin Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 57 Middle East & Africa Antithrombin Market Share, By Source, 2022 & 2030 (%)

Figure 58 CSL Limited: Financials

Figure 59 Grifols SA: Financials

Figure 60 Takeda Pharmaceuticals: Financials

Figure 61 Octapharma AG: Financials

Figure 62 LFB USA: Financials

Figure 63 Axis-Shield Plc: Financials

Figure 64 Siemens AG: Financials

Figure 65 Thermo Fisher Scientific: Financials

Figure 66 Lee Biosolutions Inc.: Financials

Figure 67 BDI Pharma: Financials

글로벌 항트롬빈 시장 – 2023-2030

Global Antithrombin Market - 2023-2030